Search Result

Results for "

SARS-CoV-2 viral RNA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (9) SARS-CoV (20) Angiotensin-converting Enzyme (ACE) (1) Dengue Virus (1) DNA Methyltransferase (1) Drug Derivative (2) Endogenous Metabolite (2) Filovirus (2) Flavivirus (2) Glycosyltransferase (1) HBV (2) HCV (2) Influenza Virus (1) Lactate Dehydrogenase (2) Nucleoside Antimetabolite/Analog (1) Reverse Transcriptase (2) Virus Protease (1)
By Research Areas:	Infection (20)

Inhibitors & Agonists

Recombinant Proteins

Targets Recommended: SARS-CoV MicroRNA mRNA RNA MTase Small Interfering RNA (siRNA) DNA/RNA Synthesis Aminoacyl-tRNA Synthetase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18649

Galidesivir hydrochloride Maximum Cited Publications 12 Publications Verification BCX4430 hydrochloride; Immucillin-A hydrochloride	DNA/RNA Synthesis SARS-CoV Filovirus	Infection
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC₅₀s ranging from ~3 to ~68 μM .

HY-18649A

Galidesivir Maximum Cited Publications 12 Publications Verification BCX4430; Immucillin-A	DNA/RNA Synthesis SARS-CoV Filovirus	Infection
Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC₅₀s ranging from ~3 to ~68 μM .

HY-172760

CIM-834	SARS-CoV	Infection
CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .

HY-145994

Obeldesivir 1 Publications Verification ATV006	SARS-CoV	Infection
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .

HY-131603

Lamivudine triphosphate 3TCTP	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-128788

ddhCTP	DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase	Infection
ddhCTP is an endogenously produced pyrimidine base analog with a K_d of 17.0 nM for LLDH and an IC₅₀ of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-109072

Riamilovir	DNA/RNA Synthesis SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of *SARS-CoV-2* .

HY-131603B

Lamivudine triphosphate TEA 3TCTP TEA	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-179249

Fluoroneplanocin A-8N	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog SARS-CoV Dengue Virus	Infection
Fluoroneplanocin A-8N (Compound 3a) is an inhibitor targeting SAH hydrolase (IC₅₀ = 1.51 μM) and viral RNA polymerase. Fluoroneplanocin A-8N exhibits broad-spectrum anti-SARS-CoV-2 and dengue virus activity, with EC₅₀ values of 12.2 and 37.4 μM respectively. Fluoroneplanocin A-8N has no cytotoxicity. Fluoroneplanocin A-8N can be used for anti-positive-strand viruses .

HY-W728005

Covidcil-19	SARS-CoV	Infection
Covidcil-19 (compound C5) avidly binds to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE) with a K_d of 11 nM. Covidcil-19 stabilizes the hairpin’s folded state and impairs frameshifting in cells. Covidcil-19 reduces frameshifting efficiency of the SARS-CoV-2 FSE and does not affect SARS-CoV-2 FSE RNA levels. Covidcil-19 inhibits a process essential for SARS-CoV-2 viral propagation .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against *SARS-CoV-2* infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-170523

RU-0415529	SARS-CoV DNA Methyltransferase	Infection
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .

HY-179334

DMA-155	SARS-CoV DNA/RNA Synthesis	Infection
DMA-155 is an antiviral agent with binding activity against *SARS-CoV-2* 5'-terminal stem-loop RNAs, with affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b) and 48.6 μM (SL6), respectively. DMA-155 inhibits SARS-CoV-2 viral replication and reduces SARS-CoV-2 viral RNA levels. DMA-155 is applicable to the research of COVID-19 .

HY-162719

RH12	DNA/RNA Synthesis SARS-CoV	Infection
RH12 is a dual inhibitor for *SARS-CoV-2* related RNA-dependent RNA polymerase (RdRp, IC₅₀ is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC₅₀ is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC₅₀ of 17.5 nM .

HY-175697

Glycosyltransferase-IN-2	Glycosyltransferase SARS-CoV Angiotensin-converting Enzyme (ACE) DNA/RNA Synthesis	Infection
Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC₅₀s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits *RNA* replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research .

HY-179293

SARS-CoV-2 PLpro-IN-3	SARS-CoV Virus Protease	Infection
SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the *SARS-CoV-2* papain-like protease (PLpro), with an IC₅₀ of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC₅₀ = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC₅₀ of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations .

HY-128788A

ddhCTP trisodium solution (100 mM)	DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase	Infection
ddhCTP trisodium solution (100 mM) is an endogenously produced pyrimidine base analog with a K_d of 17.0 nM for LLDH and an IC₅₀ of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP trisodium reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP trisodium terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP trisodium can be used in studies related to viral infections, COVID-19 and Zika virus infections .

HY-183761

Antiviral agent 86	SARS-CoV	Infection
Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a K_a value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and *SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral* double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .

HY-179556

SARS-CoV-2 nsp14-IN-10	SARS-CoV	Infection
SARS-CoV-2 nsp14-IN-10 is a highly potent and selective NSP14 (IC₅₀ = 0.34 µM) S-adenosylmethionine (SAM) binding pocket inhibitor. SARS-CoV-2 nsp14-IN-10 demonstrates robust antiviral activity against SARS-CoV-2. SARS-CoV-2 nsp14-IN-10 exhibits broad-spectrum activity against other betacoronaviruses and inhibits SARS-CoV-2 at the replication stage. SARS-CoV-2 nsp14-IN-10 suppresses viral translation and exhibits immunostimulatory effects. SARS-CoV-2 nsp14-IN-10 specifically reverses NSP14-mediated alterations inhost transcriptome. SARS-CoV-2 nsp14-IN-10 can be used for the study of SARS-CoV-2 .

Species:	Virus (3)
Tag:	His (1) Tag Free (2) Flag (1)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703529

	SARS-CoV-2 NCP N Protein (101a.a) Nucleoprotein; Nucleocapsid protein; NC; Protein N; N; Severe acute respiratory syndrome coronavirus 2; 2019-nCoV; N; Ribonucleoprotein; RNA-binding; viral nucleoprotein	Virus	E. coli
	The SARS-CoV-2 nucleocapsid protein plays a crucial role in assembling the virion, forming the helical ribonucleocapsid (RNP), and interacting with the viral genome and membrane protein M. In addition to its structural function, it also enhances subgenomic viral RNA transcription and overall replication. NCP N Protein, SARS-CoV-2 (N269-K369) is the recombinant virus-derived NCP N, expressed by E. coli, with tag-free.

HY-P703530

	SARS-CoV-2 NCP N Protein (126a.a) Nucleoprotein; Nucleocapsid protein; NC; Protein N; N; Severe acute respiratory syndrome coronavirus 2; 2019-nCoV; N; Ribonucleoprotein; RNA-binding; viral nucleoprotein	Virus	E. coli
	The SARS-CoV-2 nucleocapsid protein plays a crucial role in assembling the virion, forming the helical ribonucleocapsid (RNP), and interacting with the viral genome and membrane protein M. In addition to its structural function, it also enhances subgenomic viral RNA transcription and overall replication. NCP N Protein, SARS-CoV-2 (N48-A173) is the recombinant virus-derived NCP N, expressed by E. coli, with tag-free.

HY-P703531

	SARS-CoV-2 NCP N Protein (sf9, His, Flag) Nucleoprotein; Nucleocapsid protein; NC; Protein N; N; Severe acute respiratory syndrome coronavirus 2; 2019-nCoV; N; Ribonucleoprotein; RNA-binding; viral nucleoprotein	Virus	Sf9 insect cells
	The SARS-CoV-2 nucleocapsid protein plays a crucial role in assembling the virion, forming the helical ribonucleocapsid (RNP), and interacting with the viral genome and membrane protein M. In addition to its structural function, it also enhances subgenomic viral RNA transcription and overall replication. NCP N Protein, SARS-CoV-2 (Sf9, His, Flag) is the recombinant virus-derived NCP N, expressed by Sf9 insect cells, with His, Flag labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.